Crossmark

Genomic, phenomic and geographic associations of leukocyte telomere length in the United States

Crossref DOI link: https://doi.org/10.1038/s41588-026-02567-1

Published Online: 2026-03-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nakao, Tetsushi https://orcid.org/0000-0001-9979-2682
Koyama, Satoshi https://orcid.org/0000-0002-9286-0360
Truong, Buu https://orcid.org/0000-0003-0043-0812
Uddin, Md Mesbah https://orcid.org/0000-0003-1846-0411
Misra, Anika https://orcid.org/0009-0002-6217-0948
Patel, Aniruddh P.

Bhatnagar, Aarushi https://orcid.org/0009-0004-4699-6779
Viscosi, Victoria

Vlasschaert, Caitlyn

Bick, Alexander G. https://orcid.org/0000-0001-5824-9595
Nelson, Christopher P.

Codd, Veryan

Samani, Nilesh J.

Hornsby, Whitney

Ellinor, Patrick T.

Natarajan, Pradeep https://orcid.org/0000-0001-8402-7435
Funding

Funding for this research was provided by:

U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL168894)

U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (K99HL165024)

U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (K99HL169733)

U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (K08HL168238)
License Information

Text and Data Mining valid from 2026-03-27

Version of Record valid from 2026-03-27
More Information

Article History

Received: 13 November 2024

Accepted: 27 February 2026

First Online: 27 March 2026

Competing interests

: P.N. reports research grants from Allelica, Amgen, Apple, Boston Scientific, Cleerly, Genentech/Roche, Ionis, Novartis and Silence Therapeutics, personal fees from AIRNA, Allelica, Apple, AstraZeneca, Bain Capital, Blackstone Life Sciences, Bristol Myers Squibb, Creative Education Concepts, CRISPR Therapeutics, Eli Lilly and Company, Esperion Therapeutics, Foresite Capital, Foresite Labs, Genentech/Roche, GV, HeartFlow, Magnet Biomedicine, Merck, Novartis, Novo Nordisk, TenSixteen Bio and Tourmaline Bio, equity in Bolt, Candela, Mercury, MyOme, Parameter Health, Preciseli and TenSixteen Bio, royalties from Recora for intensive cardiac rehabilitation and spousal employment at Vertex Pharmaceuticals, all unrelated to the present work. T.N. reports speaker fees from Kowa Company, unrelated to the present work. The remaining authors declare no competing interests.

Document is current

Any future updates will be listed below